Table 4.
Clinical Features | Group | n | miR-30a-3p | miR-146b-5p | miR-199b-5p | |||
---|---|---|---|---|---|---|---|---|
Expression Level | p | Expression Level | p | Expression Level | p | |||
Age | ≥45 | 21 | −2.56 (−3.32–−1.27) | 0.547 | 3.44 (0.97–3.69) | 0.705 | −2.54 (−3.39–−1.92) | 0.319 * |
˂45 | 15 | −1.54 (−4.39–−0.27) | 1.94 (0.97–4.97) | −1.81 (−3.67–−0.13) | ||||
Sex | Male | 7 | −1.73 (−3.62–0.60) | 0.670 | 3.62 (1.12–6.12) | 0.279 | −0.56 (−2.84–0.17) | 0.092 * |
Female | 29 | −2.099 (−3.69–−0.84) | 2.61 (0.16–4.08) | −2.54 (−3.85–−1.33) | ||||
Tumor size | ≤1 cm | 14 | −1.61 (−3.88–0.33) | 0.482 | 3.57 (1.05–4.97) | 0.352 | −1.63 (−2.97–0.11) | 0.125 * |
˃1 cm | 22 | −2.329 (−3.50–−1.26) | 2.51 (−1.4–4.06) | −2.67 (−5.28–−1.73) | ||||
Number of foci | Single lesion | 20 | −1.97 (−3.17–−1.23) | 0.058 | 3.84 (2.36–5.21) | 0.339 | −1.38 (−3.18–0.17) | 0.650 * |
Multiple lesions | 16 | −3.60 (−4.72–−2.93) | 3.47 (1.15–4.33) | −1.98 (−2.71–−1.22) | ||||
Extrathyroidal extension | NO | 27 | −2.93 (−4.56–−1.56) | 0.435 | 3.69 (1.15–5.10) | 0.678 | −2.51 (−2.97–−1.29) | 0.047 * |
YES | 9 | −1.97 (−3.52–−1.47) | 3.73 (3.05–3.96) | 0.21 (−1.80–0.44) | ||||
Lymph node metastasis | N0 | 15 | −3.15 (−3.88–−1.56) | 0.679 | 3.63 (1.15–4.06) | 0.303 | −2.54 (−3.39–−1.92) | 0.010 # |
N1a | 9 | −2.37 (−3.60–−1.97) | 3.80 (3.47–5.45) | –2.61 (−3.65–−1.22) | ||||
N1b | 12 | −1.65 (−4.56–0.87) | 4.97 (1.27–5.75) | 0.10 (−0.62–0.29) |
The expression values were calculated by (−∆∆CT) miRNA expression levels are presented as the median and interquartile AJCC TNM staging the seventh edition [19]. * Using the Mann-Whitney U test, # Using the Kruskal-Wallis H test.